<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Xie Y</submitter><funding>National Institute of Environmental Health Sciences</funding><funding>National Institute of Diabetes and Digestive and Kidney Diseases</funding><funding>NIDDK NIH HHS</funding><funding>NIEHS NIH HHS</funding><funding>NCI NIH HHS</funding><pagination>1123-1139</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9035576</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>6(5)</volume><pubmed_abstract>The oxysterol receptor liver X receptor (LXR) is a nuclear receptor best known for its function in the regulation of lipid and cholesterol metabolism. LXRs, both the α and β isoforms, have been suggested as potential therapeutic targets for several cancer types. However, there was a lack of report on whether and how LXRα plays a role in the development of hepatocellular carcinoma (HCC). In the current study, we found that systemic activation of LXRα in the VP-LXRα knock-in (LXRαKI) mice or hepatocyte-specific activation of LXRα in the VP-LXRα transgenic mice sensitized mice to liver tumorigenesis induced by the combined treatment of diethylnitrosamine (DEN) and 3,3',5,5'-tetrachloro-1,4-bis (pyridyloxy) benzene (TCPOBOP). Mechanistically, the LXRα-responsive up-regulation of interleukin-6 </pubmed_abstract><journal>Hepatology communications</journal><pubmed_title>Chronic Activation of LXRα Sensitizes Mice to Hepatocellular Carcinoma.</pubmed_title><pmcid>PMC9035576</pmcid><funding_grant_id>P30 DK120531</funding_grant_id><funding_grant_id>DK117370</funding_grant_id><funding_grant_id>P30 CA047904</funding_grant_id><funding_grant_id>R35 ES030429</funding_grant_id><funding_grant_id>ES030429</funding_grant_id><funding_grant_id>R01 DK117370</funding_grant_id><pubmed_authors>Xie W</pubmed_authors><pubmed_authors>Guan J</pubmed_authors><pubmed_authors>Xu M</pubmed_authors><pubmed_authors>Xie Y</pubmed_authors><pubmed_authors>Xu P</pubmed_authors><pubmed_authors>Bell A</pubmed_authors><pubmed_authors>Ma X</pubmed_authors><pubmed_authors>Zhang M</pubmed_authors><pubmed_authors>Monga SP</pubmed_authors><pubmed_authors>Yang D</pubmed_authors><pubmed_authors>Wang J</pubmed_authors><pubmed_authors>Lu B</pubmed_authors><pubmed_authors>Liu Y</pubmed_authors><pubmed_authors>Zhu J</pubmed_authors><pubmed_authors>Sun R</pubmed_authors><pubmed_authors>Gao L</pubmed_authors><pubmed_authors>Lu P</pubmed_authors><pubmed_authors>Ren S</pubmed_authors><pubmed_authors>Cai X</pubmed_authors></additional><is_claimable>false</is_claimable><name>Chronic Activation of LXRα Sensitizes Mice to Hepatocellular Carcinoma.</name><description>The oxysterol receptor liver X receptor (LXR) is a nuclear receptor best known for its function in the regulation of lipid and cholesterol metabolism. LXRs, both the α and β isoforms, have been suggested as potential therapeutic targets for several cancer types. However, there was a lack of report on whether and how LXRα plays a role in the development of hepatocellular carcinoma (HCC). In the current study, we found that systemic activation of LXRα in the VP-LXRα knock-in (LXRαKI) mice or hepatocyte-specific activation of LXRα in the VP-LXRα transgenic mice sensitized mice to liver tumorigenesis induced by the combined treatment of diethylnitrosamine (DEN) and 3,3',5,5'-tetrachloro-1,4-bis (pyridyloxy) benzene (TCPOBOP). Mechanistically, the LXRα-responsive up-regulation of interleukin-6 </description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 May</publication><modification>2026-05-07T03:19:52.127Z</modification><creation>2025-04-04T19:32:17.356Z</creation></dates><accession>S-EPMC9035576</accession><cross_references><pubmed>34981658</pubmed><doi>10.1002/hep4.1880</doi></cross_references></HashMap>